Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment.

Abstract

OBJECTIVE:

The goal of this study was to evaluate the effects of the addition of tandospirone, a serotonin-1A (5-HT(1A)) agonist, to ongoing treatment with typical antipsychotic drugs, on two cognitive domains that are relevant to functional outcome in patients with schizophrenia.

METHOD:

Twenty-six patients with schizophrenia who were receiving stable doses of typical antipsychotics were randomly assigned to adjunctive treatment with 30 mg/day of tandospirone or placebo for 6 weeks. Executive function and verbal memory as well as psychopathology were assessed at baseline and after 6 weeks.

RESULTS:

Both cognitive measures improved significantly in the patients who received tandospirone; subjects who did not receive tandospirone showed no change. There was no significant change in psychopathology ratings in either group.

CONCLUSIONS:

The results suggest the usefulness of 5-HT(1A) agonists for enhancing some types of cognitive performance and possibly social and work function in patients with schizophrenia.

• Authors: T Sumiyoshi, M Matsui, S Nohara, I Yamashita, M Kurachi, C Sumiyoshi, K Jayathilake, H Y Meltzer
• Journal: The American journal of psychiatry (Am J Psychiatry) Vol. 158 Issue 10 Pg. 1722-5 (Oct 2001) ISSN: 0002-953X [Print] United States
• PMID: 11579010 (Publication Type: Clinical Trial, Journal Article, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)

Chemical References

• Antipsychotic Agents
• Isoindoles
• Piperazines
• Pyrimidines
• Serotonin Receptor Agonists
• tandospirone

Topics

• Antipsychotic Agents (therapeutic use)
• Cognition Disorders (drug therapy)
• Drug Therapy, Combination
• Humans
• Isoindoles
• Piperazines (therapeutic use)
• Pyrimidines (therapeutic use)
• Schizophrenia (drug therapy)
• Schizophrenic Psychology
• Serotonin Receptor Agonists (therapeutic use)
• Treatment Outcome